董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stacy Enxing Seng | 女 | Independent Director | 61 | 27.05万美元 | 1.18 | 2026-01-26 |
| Francesco Bianchi | 男 | Independent Director | 69 | 27.46万美元 | 0.90 | 2026-01-26 |
| Sharon O'Kane | 女 | Independent Director | 58 | 27.05万美元 | 1.13 | 2026-01-26 |
| Susan Podlogar | 女 | Independent Director | 62 | 25.96万美元 | 0.21 | 2026-01-26 |
| Peter Wilver | 男 | Independent Director | 66 | 27.46万美元 | 0.67 | 2026-01-26 |
| William Kozy | 男 | Director and Chairman | 74 | 40.05万美元 | 3.26 | 2026-01-26 |
| Todd Schermerhorn | 男 | Independent Director | 65 | 28.05万美元 | 0.91 | 2026-01-26 |
| Chris Barry | 男 | Independent Director | 53 | 27.46万美元 | 未持股 | 2026-01-26 |
| Vladimir Makatsaria | 男 | Director and Chief Executive Officer | 53 | 804.72万美元 | 1.42 | 2026-01-26 |
| Brooke Story | 女 | Independent Director | 54 | 25.96万美元 | 0.62 | 2026-01-26 |
| Donald J. Zurbay | 男 | Director | 58 | 16.94万美元 | 未持股 | 2026-01-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alex Shvartsburg | 男 | Chief Financial Officer | 56 | 287.59万美元 | 4.46 | 2026-01-26 |
| Vladimir Makatsaria | 男 | Director and Chief Executive Officer | 53 | 804.72万美元 | 1.42 | 2026-01-26 |
| Stephanie Bolton | 女 | President, Global Epilepsy | 44 | 未披露 | 未持股 | 2026-01-26 |
| Franco Poletti | 男 | President, Cardiopulmonary | 64 | 221.88万美元 | 未持股 | 2026-01-26 |
| Ahmet Tezel | 男 | Chief Innovation Officer | 51 | 271.91万美元 | 0.42 | 2026-01-26 |
董事简历
中英对照 | 中文 | 英文- Stacy Enxing Seng
-
Stacy Enxing SengEnxing Seng女士是董事会的新提名董事。她最后担任柯惠医疗（Covidien）的驻企高管，从2012年到2014年，担任柯惠医疗的血管治疗部门的总裁；从2010年到2012年，担任外围血管部的总裁。Enxing Seng女士在柯惠医疗于2010年以26亿美元收购ev3 Incorporated后加入柯惠医疗，从2001年到2010年，她是ev3 Incorporated的创始成员，并担任执行官，负责领导ev3的外围血管部门。在这之前，她担任过SCIMED、Boston Scientific、American Hospital Supply和Baxter的职责递增的多个职位。她目前担任 Sonova Holding AG、Solace Therapeutics的董事，在这之前，担任FIRE 1 Medical Incubator和CV Ingenuity的董事。
Stacy Enxing Seng,has served as an Operating Partner with Lightstone Ventures, a venture capital group focused on medical technology and biotechnology-related investments, since 2016. Prior to joining Lightstone Ventures, Ms. Enxing Seng was with Covidien, a global healthcare products company, as its President, Vascular Therapies (2011 to 2014) and President, Peripheral Vascular (2010 to 2011). Ms. Enxing Seng joined Covidien in 2010 through the $2.6 billion acquisition of ev3 Incorporated, where she was a founding member and executive officer, responsible for leading its Peripheral Vascular division (2001 to 2010). Prior to ev3, Ms. Enxing Seng held positions of increasing responsibility with Boston Scientific, SCIMED, Baxter, and American Hospital Supply. She holds a BA in Public Policy from Michigan State University and an MBA from Harvard University. - Stacy Enxing SengEnxing Seng女士是董事会的新提名董事。她最后担任柯惠医疗（Covidien）的驻企高管，从2012年到2014年，担任柯惠医疗的血管治疗部门的总裁；从2010年到2012年，担任外围血管部的总裁。Enxing Seng女士在柯惠医疗于2010年以26亿美元收购ev3 Incorporated后加入柯惠医疗，从2001年到2010年，她是ev3 Incorporated的创始成员，并担任执行官，负责领导ev3的外围血管部门。在这之前，她担任过SCIMED、Boston Scientific、American Hospital Supply和Baxter的职责递增的多个职位。她目前担任 Sonova Holding AG、Solace Therapeutics的董事，在这之前，担任FIRE 1 Medical Incubator和CV Ingenuity的董事。
- Stacy Enxing Seng,has served as an Operating Partner with Lightstone Ventures, a venture capital group focused on medical technology and biotechnology-related investments, since 2016. Prior to joining Lightstone Ventures, Ms. Enxing Seng was with Covidien, a global healthcare products company, as its President, Vascular Therapies (2011 to 2014) and President, Peripheral Vascular (2010 to 2011). Ms. Enxing Seng joined Covidien in 2010 through the $2.6 billion acquisition of ev3 Incorporated, where she was a founding member and executive officer, responsible for leading its Peripheral Vascular division (2001 to 2010). Prior to ev3, Ms. Enxing Seng held positions of increasing responsibility with Boston Scientific, SCIMED, Baxter, and American Hospital Supply. She holds a BA in Public Policy from Michigan State University and an MBA from Harvard University.
- Francesco Bianchi
-
Francesco Bianchi，2015年10月被任命到LivaNova董事会。此前，他从2015年8月起在Sorin 董事会任职。在主要国际金融机构（如JPMorgan Chase Paris, Morgan Grenfell （Milan）， Citi （London）和Bankers Trust （Milan），曾担任总经理和并购、企业财务主管）工作，使他获得30年的并购和战略咨询经验。曾在前意大利国有实体-Efim 清算顾问。他还主管意大利和国外Banca-Intesa S.p.A。 的战略计划部。目前，他是Intesasanpaolo Supervisory Board 的成员，以及是Maggio Fiorentino Theatre Foundation的临时管理。毕业于Florence大学并持有经济科学学位，是特许会计师。
Francesco Bianchi,serves as Chair of Seven Capital Partners S.r.l., a financial consulting firm, a position he assumed in June 2018. He previously served as the Chief Executive Officer of Seven Capital Partners and has been with the firm since 2013. Mr. Bianchi has over 30 years of mergers and acquisitions and strategic advisory experience working for well-recognized international financial institutions including JPMorgan Chase (Paris), Morgan Grenfell (London), Citi (Milan), and Bankers Trust (Milan), where he served in various roles including general manager and head of the mergers and acquisitions and corporate finance division. He also headed the strategic planning division of Banca-Intesa S.p.A. in Italy and abroad. Mr. Bianchi earned a degree in economic sciences with honors from the University of Florence and is a chartered accountant. - Francesco Bianchi，2015年10月被任命到LivaNova董事会。此前，他从2015年8月起在Sorin 董事会任职。在主要国际金融机构（如JPMorgan Chase Paris, Morgan Grenfell （Milan）， Citi （London）和Bankers Trust （Milan），曾担任总经理和并购、企业财务主管）工作，使他获得30年的并购和战略咨询经验。曾在前意大利国有实体-Efim 清算顾问。他还主管意大利和国外Banca-Intesa S.p.A。 的战略计划部。目前，他是Intesasanpaolo Supervisory Board 的成员，以及是Maggio Fiorentino Theatre Foundation的临时管理。毕业于Florence大学并持有经济科学学位，是特许会计师。
- Francesco Bianchi,serves as Chair of Seven Capital Partners S.r.l., a financial consulting firm, a position he assumed in June 2018. He previously served as the Chief Executive Officer of Seven Capital Partners and has been with the firm since 2013. Mr. Bianchi has over 30 years of mergers and acquisitions and strategic advisory experience working for well-recognized international financial institutions including JPMorgan Chase (Paris), Morgan Grenfell (London), Citi (Milan), and Bankers Trust (Milan), where he served in various roles including general manager and head of the mergers and acquisitions and corporate finance division. He also headed the strategic planning division of Banca-Intesa S.p.A. in Italy and abroad. Mr. Bianchi earned a degree in economic sciences with honors from the University of Florence and is a chartered accountant.
- Sharon O'Kane
-
Sharon O'Kane于2015年10月被任命为LivaNova公司董事会。目前，O’Kane博士是University College Dublin住宅的企业家，并且任职ScarX Therapeutics Inc.（一家加拿大生物技术公司）的临床/科学顾问委员会。O’Kane博士还任职Bank End Properties 1 Ltd.和Bank End Properties 2 Ltd.的董事会。O’Kane博士是GSK的Stevenage催化剂设施的专家顾问。此前，2010年4月至2016年1月O’Kane博士任职IOmet Pharma LTD的董事会。此外，2009年至2014年O’Kane博士是曼彻斯特知识产权公司大学（UMIP）的住宅的企业家；2011年至2013年，担任University of Manchester药物发现咨询委员会的主席。2011年至2013，她也是University of Manchester生命科学院的外部商业顾问委员会的成员；2010至2012年，O’Kane博士是Manchester Inward发展局的非执行董事和Greater Manchester Authorities’ Centre of Excellence运营委员会的成员。O’Kane博士共同创立，并1998年至2010年是Renovo Group PLC“Renovo”（一家上市英国的生物技术公司）的首席科技官兼执行董事。自2002年以来，O’Kane博士一直是董事学会的成员，并拥有董事学会公司方向的文凭。
Sharon O'Kane,serves as a non-executive director and member of the Audit and Risk Committee of the Health Products Regulatory Authority Board in Ireland and has a Visiting Professorship at Ulster University where she advises the Faculty of Life and Health Sciences. She has also served as an Entrepreneur in Residence at University College Dublin since 2015. She was a non-executive director of Iomet Pharma Ltd (2010-2016), an expert advisor to the Stevenage Bioscience Catalyst Facility at GlaxoSmithKline, (2012 to 2019) and a Commercial Mentor to Queen's University, Belfast (2016 to 2019). Previously, Dr. O'Kane served as Entrepreneur in Residence at the University of Manchester Intellectual Property Company UMIP (2009 to 2014) and was a non-executive director of the Manchester Inward development agency (2010-2012). Dr. O'Kane co-founded and, from 1998 to 2010, was the Chief Scientific Officer and a Director of Renovo Group Plc, a UK biotech company. Dr. O'Kane earned a Bachelor of Science (Honours) First Class in Biomedical Sciences from the University of Ulster from which she also earned a PhD in Biomedical Sciences. She earned a Diploma in Company Direction from the Institute of Directors (UK), where she was recently made a Chartered Director and Fellow of the Institute and received corporate governance training at Harvard Business School. - Sharon O'Kane于2015年10月被任命为LivaNova公司董事会。目前，O’Kane博士是University College Dublin住宅的企业家，并且任职ScarX Therapeutics Inc.（一家加拿大生物技术公司）的临床/科学顾问委员会。O’Kane博士还任职Bank End Properties 1 Ltd.和Bank End Properties 2 Ltd.的董事会。O’Kane博士是GSK的Stevenage催化剂设施的专家顾问。此前，2010年4月至2016年1月O’Kane博士任职IOmet Pharma LTD的董事会。此外，2009年至2014年O’Kane博士是曼彻斯特知识产权公司大学（UMIP）的住宅的企业家；2011年至2013年，担任University of Manchester药物发现咨询委员会的主席。2011年至2013，她也是University of Manchester生命科学院的外部商业顾问委员会的成员；2010至2012年，O’Kane博士是Manchester Inward发展局的非执行董事和Greater Manchester Authorities’ Centre of Excellence运营委员会的成员。O’Kane博士共同创立，并1998年至2010年是Renovo Group PLC“Renovo”（一家上市英国的生物技术公司）的首席科技官兼执行董事。自2002年以来，O’Kane博士一直是董事学会的成员，并拥有董事学会公司方向的文凭。
- Sharon O'Kane,serves as a non-executive director and member of the Audit and Risk Committee of the Health Products Regulatory Authority Board in Ireland and has a Visiting Professorship at Ulster University where she advises the Faculty of Life and Health Sciences. She has also served as an Entrepreneur in Residence at University College Dublin since 2015. She was a non-executive director of Iomet Pharma Ltd (2010-2016), an expert advisor to the Stevenage Bioscience Catalyst Facility at GlaxoSmithKline, (2012 to 2019) and a Commercial Mentor to Queen's University, Belfast (2016 to 2019). Previously, Dr. O'Kane served as Entrepreneur in Residence at the University of Manchester Intellectual Property Company UMIP (2009 to 2014) and was a non-executive director of the Manchester Inward development agency (2010-2012). Dr. O'Kane co-founded and, from 1998 to 2010, was the Chief Scientific Officer and a Director of Renovo Group Plc, a UK biotech company. Dr. O'Kane earned a Bachelor of Science (Honours) First Class in Biomedical Sciences from the University of Ulster from which she also earned a PhD in Biomedical Sciences. She earned a Diploma in Company Direction from the Institute of Directors (UK), where she was recently made a Chartered Director and Fellow of the Institute and received corporate governance training at Harvard Business School.
- Susan Podlogar
-
Susan Podlogar，大都会人寿公司执行副总裁兼首席人力资源官，2017年7月至今。强生医疗器械、医药和消费品公司（2016年5月至2017年6月）全球医疗器械人力资源副总裁。EMEA人力资源副总裁，全球Total Rewards，强生（2015年1月-2016年5月）。
Susan Podlogar,served as the Executive Vice President, Chief Human Resources Officer at MetLife from July 2017 until her retirement in June 2024. Prior to MetLife, Ms. Podlogar spent 16 years at Johnson & Johnson in various leadership roles, including Global Head, Human Resources Medical Devices; Global Head of Total Rewards and Head Human Resources for Europe, the Middle East, and Africa; and Global Head, Human Resources and Communications Pharmaceutical R&D. Early career highlights include positions with Bayer Pharmaceutical, Bristol-Myers Squibb, and William M. Mercer. She holds an MBA from the University of South Florida and a bachelor's degree with a double major in Labor and Industrial Relations and Business Administration from the University of Wisconsin-Parkside. - Susan Podlogar，大都会人寿公司执行副总裁兼首席人力资源官，2017年7月至今。强生医疗器械、医药和消费品公司（2016年5月至2017年6月）全球医疗器械人力资源副总裁。EMEA人力资源副总裁，全球Total Rewards，强生（2015年1月-2016年5月）。
- Susan Podlogar,served as the Executive Vice President, Chief Human Resources Officer at MetLife from July 2017 until her retirement in June 2024. Prior to MetLife, Ms. Podlogar spent 16 years at Johnson & Johnson in various leadership roles, including Global Head, Human Resources Medical Devices; Global Head of Total Rewards and Head Human Resources for Europe, the Middle East, and Africa; and Global Head, Human Resources and Communications Pharmaceutical R&D. Early career highlights include positions with Bayer Pharmaceutical, Bristol-Myers Squibb, and William M. Mercer. She holds an MBA from the University of South Florida and a bachelor's degree with a double major in Labor and Industrial Relations and Business Administration from the University of Wisconsin-Parkside.
- Peter Wilver
-
Peter Wilver于2021年1月加入公司担任董事。Wilver先生于2015年8月至2017年3月退休期间担任赛默飞世尔科技公司“赛默飞世尔”的执行副总裁兼首席行政官，该公司是一家领先的实验室产品和服务提供商，此前曾于2004年10月至2015年7月期间担任赛默飞世尔（前身为Thermo Electron）的首席财务官已有11年。在2000年加入Thermo Electron之前，Wilver先生曾在通用电气和Grimes Aerospace公司担任财务领导职务，在霍尼韦尔担任财务领导职务，最近担任电子材料业务的副总裁兼首席财务官。Wilver先生目前在CIRCOR International（其为审计委员会和薪酬委员会成员）以及Evoqua Water Technologies（其为审计委员会主席和薪酬委员会成员）的董事会任职，此前在泰尼特保健（其为审计委员会和人力资源委员会成员）任职。Wilver先生是一名注册会计师。Wilver先生拥有俄亥俄州立大学会计学学士学位（以优异成绩）。
Peter Wilver joined the Company as a director in January 2021. Mr. Wilver was Executive Vice President and Chief Administrative Officer of Thermo Fisher Scientific Inc. "Thermo Fisher", a leading provider of laboratory products and services, from August 2015 until his retirement in March 2017 and had previously spent 11 years as the Chief Financial Officer of Thermo Fisher (formerly Thermo Electron) from October 2004 until July 2015. Before joining Thermo Electron in 2000 Mr. Wilver held financial leadership roles at General Electric and Grimes Aerospace Company, and at Honeywell International, where he most recently served as Vice President and Chief Financial Officer of the electronic materials business. Mr. Wilver currently serves on the Board of Directors of CIRCOR International, where he is a member of the Audit and Compensation Committees, and Evoqua Water Technologies, where he is Chair of the Audit Committee and a member of the Compensation Committee, and previously Tenet Healthcare, where he was a member of the Audit and Human Resources Committees. Mr. Wilver is a certified public accountant. Mr. Wilver holds a B.S.B.A. degree (summa cum laude) in Accounting from The Ohio State University. - Peter Wilver于2021年1月加入公司担任董事。Wilver先生于2015年8月至2017年3月退休期间担任赛默飞世尔科技公司“赛默飞世尔”的执行副总裁兼首席行政官，该公司是一家领先的实验室产品和服务提供商，此前曾于2004年10月至2015年7月期间担任赛默飞世尔（前身为Thermo Electron）的首席财务官已有11年。在2000年加入Thermo Electron之前，Wilver先生曾在通用电气和Grimes Aerospace公司担任财务领导职务，在霍尼韦尔担任财务领导职务，最近担任电子材料业务的副总裁兼首席财务官。Wilver先生目前在CIRCOR International（其为审计委员会和薪酬委员会成员）以及Evoqua Water Technologies（其为审计委员会主席和薪酬委员会成员）的董事会任职，此前在泰尼特保健（其为审计委员会和人力资源委员会成员）任职。Wilver先生是一名注册会计师。Wilver先生拥有俄亥俄州立大学会计学学士学位（以优异成绩）。
- Peter Wilver joined the Company as a director in January 2021. Mr. Wilver was Executive Vice President and Chief Administrative Officer of Thermo Fisher Scientific Inc. "Thermo Fisher", a leading provider of laboratory products and services, from August 2015 until his retirement in March 2017 and had previously spent 11 years as the Chief Financial Officer of Thermo Fisher (formerly Thermo Electron) from October 2004 until July 2015. Before joining Thermo Electron in 2000 Mr. Wilver held financial leadership roles at General Electric and Grimes Aerospace Company, and at Honeywell International, where he most recently served as Vice President and Chief Financial Officer of the electronic materials business. Mr. Wilver currently serves on the Board of Directors of CIRCOR International, where he is a member of the Audit and Compensation Committees, and Evoqua Water Technologies, where he is Chair of the Audit Committee and a member of the Compensation Committee, and previously Tenet Healthcare, where he was a member of the Audit and Human Resources Committees. Mr. Wilver is a certified public accountant. Mr. Wilver holds a B.S.B.A. degree (summa cum laude) in Accounting from The Ohio State University.
- William Kozy
-
William Kozy于2016年从全球医疗技术公司碧迪医疗器械有限公司退休，在那里他从2011年至2016年担任执行副总裁兼首席运营官。在Becton Dickinson，他也曾担任公司领导团队的成员，也曾担任多种执行职务（1988年以来），包括BD Medical公司的负责人（2009年至2011年），BD Biosciences部门的总裁（2006年至2009年），BD Diagnostics的总裁（2002年至2006年）和公司运营的高级副总裁（1998年至2002年）。Kozy先生拥有凯尼恩学院的学士学位。
William Kozy,is the Chair of the Board of Directors of LivaNova. Mr. Kozy previously served as Interim Chief Executive Officer of LivaNova from April 2023 to February 2024. Mr. Kozy retired from Becton, Dickinson and Company, a global medical technology company, in 2016 where Mr. Kozy served as Executive Vice President and Chief Operating Officer from 2011 to 2016. During his time at Becton Dickinson, he was responsible for all worldwide businesses of the company with leadership emphasis on profitable revenue growth and talent development At Becton Dickinson, he also served as a member of the corporate leadership team and in various executive roles since 1988, including head of BD Medical (2009 to 2011), President of the BD Biosciences segment (2006 to 2009), President of BD Diagnostics (2002 to 2006) and Senior Vice President of Company Operations (1998 to 2002). Mr. Kozy holds a BA from Kenyon College. - William Kozy于2016年从全球医疗技术公司碧迪医疗器械有限公司退休，在那里他从2011年至2016年担任执行副总裁兼首席运营官。在Becton Dickinson，他也曾担任公司领导团队的成员，也曾担任多种执行职务（1988年以来），包括BD Medical公司的负责人（2009年至2011年），BD Biosciences部门的总裁（2006年至2009年），BD Diagnostics的总裁（2002年至2006年）和公司运营的高级副总裁（1998年至2002年）。Kozy先生拥有凯尼恩学院的学士学位。
- William Kozy,is the Chair of the Board of Directors of LivaNova. Mr. Kozy previously served as Interim Chief Executive Officer of LivaNova from April 2023 to February 2024. Mr. Kozy retired from Becton, Dickinson and Company, a global medical technology company, in 2016 where Mr. Kozy served as Executive Vice President and Chief Operating Officer from 2011 to 2016. During his time at Becton Dickinson, he was responsible for all worldwide businesses of the company with leadership emphasis on profitable revenue growth and talent development At Becton Dickinson, he also served as a member of the corporate leadership team and in various executive roles since 1988, including head of BD Medical (2009 to 2011), President of the BD Biosciences segment (2006 to 2009), President of BD Diagnostics (2002 to 2006) and Senior Vice President of Company Operations (1998 to 2002). Mr. Kozy holds a BA from Kenyon College.
- Todd Schermerhorn
-
Todd Schermerhorn，于2003年至2012年退休期间，担任生命增强医疗技术的跨国开发商、制造商和营销商华润巴德公司的高级副总裁兼首席财务官。在此之前，他曾担任华润巴德副总裁兼财务主管（1998-2003年）。从1985年到1998年，Schermerhorn先生曾在华润巴德担任其他多个管理职务。Schermerhorn先生获得了洛厄尔大学的学士学位和巴布森学院的MBA学位。
Todd Schermerhorn,served as the Senior Vice President and Chief Financial Officer of C. R. Bard, Inc., a multinational developer, manufacturer, and marketer of life-enhancing medical technologies, from 2003 until his retirement in 2012. Prior to that, he had been Vice President and Treasurer of C. R. Bard (1998 - 2003). From 1985 to 1998, Mr. Schermerhorn held various other management positions with C. R. Bard. Mr. Schermerhorn received a BS from the University of Lowell and an MBA from Babson College. - Todd Schermerhorn，于2003年至2012年退休期间，担任生命增强医疗技术的跨国开发商、制造商和营销商华润巴德公司的高级副总裁兼首席财务官。在此之前，他曾担任华润巴德副总裁兼财务主管（1998-2003年）。从1985年到1998年，Schermerhorn先生曾在华润巴德担任其他多个管理职务。Schermerhorn先生获得了洛厄尔大学的学士学位和巴布森学院的MBA学位。
- Todd Schermerhorn,served as the Senior Vice President and Chief Financial Officer of C. R. Bard, Inc., a multinational developer, manufacturer, and marketer of life-enhancing medical technologies, from 2003 until his retirement in 2012. Prior to that, he had been Vice President and Treasurer of C. R. Bard (1998 - 2003). From 1985 to 1998, Mr. Schermerhorn held various other management positions with C. R. Bard. Mr. Schermerhorn received a BS from the University of Lowell and an MBA from Babson College.
- Chris Barry
-
Chris Barry，是Solventum的MedSurg业务部门的执行副总裁兼集团总裁。他于2024年1月加入3M的医疗保健业务。Barry先生在医疗器械和技术方面拥有超过25年的经验，目前担任医疗器械公司LivaNova，PLC的董事会成员。在加入Solventum之前，他是医疗器械公司纽瓦索器材公司的首席执行官和董事会成员。在担任该职务之前，他曾在第二大业务部门美敦力担任高级副总裁兼外科创新业务总裁。在美敦力收购Covidien之前，Barry先生是Covidien的Advanced Surgical Technologies总裁，负责领导全球业务部门的全球战略、产品组合和美国商业团队。他还在Covidien担任了超过15年的商业和行政领导职务，负责增加责任。
Chris Barry,serves as Executive Vice President and Group President of the Medical Solutions Division at Solventum, formerly known as 3M, a position he assumed in March 2024. He previously served as CEO and a member of the board of NuVasive, Inc., a medical technology company focused on spine technology innovation, from 2018 to 2023, at which point, NuVasive Inc. was acquired by Globus Medical. From 2015 to 2018, Mr. Barry served as Senior Vice President and President of Surgical Innovations at Medtronic after Medtronic acquired Covidien, and, prior to Covidien's acquisition, Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien, rising to vice president of sales for energy-based devices. Mr. Barry has a Bachelor of Science degree in Environmental Science from Texas Tech University. - Chris Barry，是Solventum的MedSurg业务部门的执行副总裁兼集团总裁。他于2024年1月加入3M的医疗保健业务。Barry先生在医疗器械和技术方面拥有超过25年的经验，目前担任医疗器械公司LivaNova，PLC的董事会成员。在加入Solventum之前，他是医疗器械公司纽瓦索器材公司的首席执行官和董事会成员。在担任该职务之前，他曾在第二大业务部门美敦力担任高级副总裁兼外科创新业务总裁。在美敦力收购Covidien之前，Barry先生是Covidien的Advanced Surgical Technologies总裁，负责领导全球业务部门的全球战略、产品组合和美国商业团队。他还在Covidien担任了超过15年的商业和行政领导职务，负责增加责任。
- Chris Barry,serves as Executive Vice President and Group President of the Medical Solutions Division at Solventum, formerly known as 3M, a position he assumed in March 2024. He previously served as CEO and a member of the board of NuVasive, Inc., a medical technology company focused on spine technology innovation, from 2018 to 2023, at which point, NuVasive Inc. was acquired by Globus Medical. From 2015 to 2018, Mr. Barry served as Senior Vice President and President of Surgical Innovations at Medtronic after Medtronic acquired Covidien, and, prior to Covidien's acquisition, Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien, rising to vice president of sales for energy-based devices. Mr. Barry has a Bachelor of Science degree in Environmental Science from Texas Tech University.
- Vladimir Makatsaria
-
Vladimir Makatsaria，是LivaNova的首席执行官和董事会成员。在加入LivaNova之前，他在跨国制药和医疗技术公司强生（J & J）工作了27年，担任行政领导职务，跨越多个技术和地区。他最近在J & J MedTech担任公司集团董事长，在那里他领导了Ethicon，这是外科技术市场的全球领导者。在他的强生任期内，其他高管职位包括领导强生中国、强生医疗亚太、Ethicon EMEA等。他还曾在Ethicon、DePuy和Total MedTech全球领导团队任职。他曾担任亚太医疗技术协会（“APACMed”）董事会主席，并担任新加坡管理大学顾问委员会成员。Makatsaria先生拥有明尼苏达大学的三个学位：生理学学士学位、MBA学位和医疗保健行政管理硕士学位。
Vladimir Makatsaria,is Chief Executive Officer and a Board Member of LivaNova. Prior to LivaNova, he worked for 27 years at Johnson & Johnson (J&J), a multinational pharmaceutical and medical technologies corporation, in executive leadership roles, spanning various technologies and geographies. He most recently served as Company Group Chairman at J&J MedTech where he led Ethicon, a global leader in the surgical technologies market. Other executive positions throughout his J&J tenure include leading J&J China, J&J MedTech APAC, and Ethicon EMEA, among others. He also served on Ethicon, DePuy, and total MedTech global leadership teams. He served as Chairman of the Board of the Asia Pacific Medical Technology Association ("APACMed") and as an Advisory Board Member to Singapore Management University. Mr. Makatsaria holds three degrees from the University of Minnesota: a bachelor's degree in physiology, an MBA, and a master's in healthcare administration. - Vladimir Makatsaria，是LivaNova的首席执行官和董事会成员。在加入LivaNova之前，他在跨国制药和医疗技术公司强生（J & J）工作了27年，担任行政领导职务，跨越多个技术和地区。他最近在J & J MedTech担任公司集团董事长，在那里他领导了Ethicon，这是外科技术市场的全球领导者。在他的强生任期内，其他高管职位包括领导强生中国、强生医疗亚太、Ethicon EMEA等。他还曾在Ethicon、DePuy和Total MedTech全球领导团队任职。他曾担任亚太医疗技术协会（“APACMed”）董事会主席，并担任新加坡管理大学顾问委员会成员。Makatsaria先生拥有明尼苏达大学的三个学位：生理学学士学位、MBA学位和医疗保健行政管理硕士学位。
- Vladimir Makatsaria,is Chief Executive Officer and a Board Member of LivaNova. Prior to LivaNova, he worked for 27 years at Johnson & Johnson (J&J), a multinational pharmaceutical and medical technologies corporation, in executive leadership roles, spanning various technologies and geographies. He most recently served as Company Group Chairman at J&J MedTech where he led Ethicon, a global leader in the surgical technologies market. Other executive positions throughout his J&J tenure include leading J&J China, J&J MedTech APAC, and Ethicon EMEA, among others. He also served on Ethicon, DePuy, and total MedTech global leadership teams. He served as Chairman of the Board of the Asia Pacific Medical Technology Association ("APACMed") and as an Advisory Board Member to Singapore Management University. Mr. Makatsaria holds three degrees from the University of Minnesota: a bachelor's degree in physiology, an MBA, and a master's in healthcare administration.
- Brooke Story
-
布鲁克故事，担任碧迪医疗公司的整合负责人，她于2024年6月担任该职位。她此前曾于2023年7月至2024年3月在碧迪医疗公司担任外科全球总裁，并于2021年4月至2023年7月在碧迪医疗公司担任集成诊断解决方案全球总裁。在此之前，Story女士在美敦力工作了15年，在那里她担任过财务、销售和业务部门领导等各种职务，最终担任骨盆健康和胃疗法总裁。Story女士的职业生涯始于强生的销售部门，并曾担任埃森哲的顾问。Story女士拥有田纳西大学工业工程学士学位和密歇根大学MBA学位。
Brooke Story,serves as Integration Lead at Becton, Dickinson and Company, a position she assumed in June 2024. She previously served as the Worldwide President, Surgery at Becton, Dickinson and Company from July 2023 to March 2024 and Worldwide President, Integrated Diagnostics Solutions at Becton, Dickinson and Company from April 2021 to July 2023. Prior to that, Ms. Story spent 15 years at Medtronic, where she held a variety of roles in finance, sales, and business unit leadership, culminating in her tenure as President, Pelvic Health and Gastric Therapies. Ms. Story began her career in sales at Johnson & Johnson and as a consultant for Accenture. Ms. Story holds a BS in industrial engineering from the University of Tennessee and an MBA from the University of Michigan. - 布鲁克故事，担任碧迪医疗公司的整合负责人，她于2024年6月担任该职位。她此前曾于2023年7月至2024年3月在碧迪医疗公司担任外科全球总裁，并于2021年4月至2023年7月在碧迪医疗公司担任集成诊断解决方案全球总裁。在此之前，Story女士在美敦力工作了15年，在那里她担任过财务、销售和业务部门领导等各种职务，最终担任骨盆健康和胃疗法总裁。Story女士的职业生涯始于强生的销售部门，并曾担任埃森哲的顾问。Story女士拥有田纳西大学工业工程学士学位和密歇根大学MBA学位。
- Brooke Story,serves as Integration Lead at Becton, Dickinson and Company, a position she assumed in June 2024. She previously served as the Worldwide President, Surgery at Becton, Dickinson and Company from July 2023 to March 2024 and Worldwide President, Integrated Diagnostics Solutions at Becton, Dickinson and Company from April 2021 to July 2023. Prior to that, Ms. Story spent 15 years at Medtronic, where she held a variety of roles in finance, sales, and business unit leadership, culminating in her tenure as President, Pelvic Health and Gastric Therapies. Ms. Story began her career in sales at Johnson & Johnson and as a consultant for Accenture. Ms. Story holds a BS in industrial engineering from the University of Tennessee and an MBA from the University of Michigan.
- Donald J. Zurbay
-
Donald J. Zurbay自2018年3月起担任Silk Road Medical, Inc.的董事。Zurbay先生自2018年6月起担任Patterson公司（上市的全球医疗设备公司）的首席财务官。从2004年3月到2017年2月，Zurbay先生在St. Jude Medical, Inc.担任各种领导职务，他最近担任副总裁兼首席财务官（从2012年8月到2017年1月）。Zurbay先生曾在普华永道会计师事务所（PricewaterhouseCoopers）担任担保和商业咨询服务高级经理。加入PricewaterhouseCoopers之前，他是The Valspar Corporation的会计总经理。加入The Valspar Corporation之前，Zurbay先生是Deloitte & Touche的审计师。他是美国注册会计师协会（American Institute of Certified Accountants）和明尼苏达注册会计师协会（the Minnesota Society of Certified Public Accountants）的成员。他获得了明尼苏达大学（the University of Minnesota）的商业学士学位（侧重于会计）。
Donald J. Zurbay,became Patterson Companies, Inc. President and Chief Executive Officer in October 2022. Mr. Zurbay previously served as Patterson Companies, Inc. Chief Financial Officer from June 2018 through October 2022. Prior to that, Mr. Zurbay served as Vice President and Chief Financial Officer at global medical device manufacturer St. Jude Medical, Inc. from August 2012 through the January 2017 acquisition of St. Jude Medical by Abbott Laboratories. At St. Jude Medical, Mr. Zurbay was responsible for all accounting, financial and business development activities. He joined St. Jude Medical in 2003 and held various leadership positions, including Director of Finance and Vice President and Corporate Controller. Prior to joining St. Jude Medical, Mr. Zurbay worked at PricewaterhouseCoopers for five years as an Assurance and Business Advisory Services Senior Manager. Before joining PricewaterhouseCoopers, he was a General Accounting Manager at The Valspar Corporation. Mr. Zurbay started his career at Deloitte & Touche as an auditor in 1989. - Donald J. Zurbay自2018年3月起担任Silk Road Medical, Inc.的董事。Zurbay先生自2018年6月起担任Patterson公司（上市的全球医疗设备公司）的首席财务官。从2004年3月到2017年2月，Zurbay先生在St. Jude Medical, Inc.担任各种领导职务，他最近担任副总裁兼首席财务官（从2012年8月到2017年1月）。Zurbay先生曾在普华永道会计师事务所（PricewaterhouseCoopers）担任担保和商业咨询服务高级经理。加入PricewaterhouseCoopers之前，他是The Valspar Corporation的会计总经理。加入The Valspar Corporation之前，Zurbay先生是Deloitte & Touche的审计师。他是美国注册会计师协会（American Institute of Certified Accountants）和明尼苏达注册会计师协会（the Minnesota Society of Certified Public Accountants）的成员。他获得了明尼苏达大学（the University of Minnesota）的商业学士学位（侧重于会计）。
- Donald J. Zurbay,became Patterson Companies, Inc. President and Chief Executive Officer in October 2022. Mr. Zurbay previously served as Patterson Companies, Inc. Chief Financial Officer from June 2018 through October 2022. Prior to that, Mr. Zurbay served as Vice President and Chief Financial Officer at global medical device manufacturer St. Jude Medical, Inc. from August 2012 through the January 2017 acquisition of St. Jude Medical by Abbott Laboratories. At St. Jude Medical, Mr. Zurbay was responsible for all accounting, financial and business development activities. He joined St. Jude Medical in 2003 and held various leadership positions, including Director of Finance and Vice President and Corporate Controller. Prior to joining St. Jude Medical, Mr. Zurbay worked at PricewaterhouseCoopers for five years as an Assurance and Business Advisory Services Senior Manager. Before joining PricewaterhouseCoopers, he was a General Accounting Manager at The Valspar Corporation. Mr. Zurbay started his career at Deloitte & Touche as an auditor in 1989.
高管简历
中英对照 | 中文 | 英文- Alex Shvartsburg
Alex Shvartsburg于2017年9月加入LivaNova，担任财务战略与创新副总裁（2017年至2020年1月），然后成为国际市场公司财务与首席财务官（2020年1月至2020年11月）。他于2020年11月担任临时首席财务官。在加入公司之前，Shvartsburg先生曾担任CaligorRx的首席财务官/；首席运营官（2016年6月至2017年9月）；赛默飞世尔科学公司的副总裁金融基因科学部门（2014年1月至2016年6月）；财务总监，负责Life Technologies的并购（2012年6月至2014年1月）。在他职业生涯的早期，他担任财务方面的职务，责任越来越大。Shvartsburg先生拥有德雷塞尔大学工商管理学院会计学士学位和拉萨尔大学工商管理硕士学位。
Alex Shvartsburg,joined LivaNova in September 2017 as Vice President, Finance, Strategy & Innovation (September 2017 to January 2020) and then became Vice President, Corporate Finance & Chief Financial Officer, International Markets (January 2020 to November 2020). He assumed the role of Interim Chief Financial Officer in November 2020 and became CFO in July 2021. Prior to joining the Company, Mr. Shvartsburg was Chief Financial Officer/Chief Operating Officer of Caligor Coghlan Pharma Services (f/k/a CaligorRx), a global provider of clinical supply services (June 2016 to September 2017); Vice President, Finance Genetic Science Division at Thermo Fisher Scientific (January 2014 to June 2016); and Sr. Finance Director, Mergers & Acquisitions with Life Technologies (June 2012 to January 2014). Over the course of twenty years, Mr. Shvartsburg held positions of increasing responsibility in finance with Johnson & Johnson. Mr. Shvartsburg holds a BS in Accounting from Drexel University—College of Business and Administration and an MBA from La Salle University.- Alex Shvartsburg于2017年9月加入LivaNova，担任财务战略与创新副总裁（2017年至2020年1月），然后成为国际市场公司财务与首席财务官（2020年1月至2020年11月）。他于2020年11月担任临时首席财务官。在加入公司之前，Shvartsburg先生曾担任CaligorRx的首席财务官/；首席运营官（2016年6月至2017年9月）；赛默飞世尔科学公司的副总裁金融基因科学部门（2014年1月至2016年6月）；财务总监，负责Life Technologies的并购（2012年6月至2014年1月）。在他职业生涯的早期，他担任财务方面的职务，责任越来越大。Shvartsburg先生拥有德雷塞尔大学工商管理学院会计学士学位和拉萨尔大学工商管理硕士学位。
- Alex Shvartsburg,joined LivaNova in September 2017 as Vice President, Finance, Strategy & Innovation (September 2017 to January 2020) and then became Vice President, Corporate Finance & Chief Financial Officer, International Markets (January 2020 to November 2020). He assumed the role of Interim Chief Financial Officer in November 2020 and became CFO in July 2021. Prior to joining the Company, Mr. Shvartsburg was Chief Financial Officer/Chief Operating Officer of Caligor Coghlan Pharma Services (f/k/a CaligorRx), a global provider of clinical supply services (June 2016 to September 2017); Vice President, Finance Genetic Science Division at Thermo Fisher Scientific (January 2014 to June 2016); and Sr. Finance Director, Mergers & Acquisitions with Life Technologies (June 2012 to January 2014). Over the course of twenty years, Mr. Shvartsburg held positions of increasing responsibility in finance with Johnson & Johnson. Mr. Shvartsburg holds a BS in Accounting from Drexel University—College of Business and Administration and an MBA from La Salle University.
- Vladimir Makatsaria
Vladimir Makatsaria，是LivaNova的首席执行官和董事会成员。在加入LivaNova之前，他在跨国制药和医疗技术公司强生（J & J）工作了27年，担任行政领导职务，跨越多个技术和地区。他最近在J & J MedTech担任公司集团董事长，在那里他领导了Ethicon，这是外科技术市场的全球领导者。在他的强生任期内，其他高管职位包括领导强生中国、强生医疗亚太、Ethicon EMEA等。他还曾在Ethicon、DePuy和Total MedTech全球领导团队任职。他曾担任亚太医疗技术协会（“APACMed”）董事会主席，并担任新加坡管理大学顾问委员会成员。Makatsaria先生拥有明尼苏达大学的三个学位：生理学学士学位、MBA学位和医疗保健行政管理硕士学位。
Vladimir Makatsaria,is Chief Executive Officer and a Board Member of LivaNova. Prior to LivaNova, he worked for 27 years at Johnson & Johnson (J&J), a multinational pharmaceutical and medical technologies corporation, in executive leadership roles, spanning various technologies and geographies. He most recently served as Company Group Chairman at J&J MedTech where he led Ethicon, a global leader in the surgical technologies market. Other executive positions throughout his J&J tenure include leading J&J China, J&J MedTech APAC, and Ethicon EMEA, among others. He also served on Ethicon, DePuy, and total MedTech global leadership teams. He served as Chairman of the Board of the Asia Pacific Medical Technology Association ("APACMed") and as an Advisory Board Member to Singapore Management University. Mr. Makatsaria holds three degrees from the University of Minnesota: a bachelor's degree in physiology, an MBA, and a master's in healthcare administration.- Vladimir Makatsaria，是LivaNova的首席执行官和董事会成员。在加入LivaNova之前，他在跨国制药和医疗技术公司强生（J & J）工作了27年，担任行政领导职务，跨越多个技术和地区。他最近在J & J MedTech担任公司集团董事长，在那里他领导了Ethicon，这是外科技术市场的全球领导者。在他的强生任期内，其他高管职位包括领导强生中国、强生医疗亚太、Ethicon EMEA等。他还曾在Ethicon、DePuy和Total MedTech全球领导团队任职。他曾担任亚太医疗技术协会（“APACMed”）董事会主席，并担任新加坡管理大学顾问委员会成员。Makatsaria先生拥有明尼苏达大学的三个学位：生理学学士学位、MBA学位和医疗保健行政管理硕士学位。
- Vladimir Makatsaria,is Chief Executive Officer and a Board Member of LivaNova. Prior to LivaNova, he worked for 27 years at Johnson & Johnson (J&J), a multinational pharmaceutical and medical technologies corporation, in executive leadership roles, spanning various technologies and geographies. He most recently served as Company Group Chairman at J&J MedTech where he led Ethicon, a global leader in the surgical technologies market. Other executive positions throughout his J&J tenure include leading J&J China, J&J MedTech APAC, and Ethicon EMEA, among others. He also served on Ethicon, DePuy, and total MedTech global leadership teams. He served as Chairman of the Board of the Asia Pacific Medical Technology Association ("APACMed") and as an Advisory Board Member to Singapore Management University. Mr. Makatsaria holds three degrees from the University of Minnesota: a bachelor's degree in physiology, an MBA, and a master's in healthcare administration.
- Stephanie Bolton
Stephanie Bolton，是LivaNova全球癫痫总裁，她于2023年5月担任该职位。她于2011年4月加入LivaNova的两家遗留公司之一的Cyberonics, Inc.，担任癫痫高级区域经理（2011年3月至2014年4月），并在LivaNova任职期间，担任过多个高级销售领导职务。在担任高级区域经理后，她担任英国和爱尔兰国家经理（2014年4月至2016年9月）、UKI副总裁（2016年9月至2018年2月）和北欧副总裁（2018年2月至2019年10月）。2019年10月，Bolton女士被任命为欧洲区总裁（2019年10月至2021年2月），之后成为LivaNova国际区总裁（2021年2月至2023年5月），之后她担任目前的全球癫痫总裁一职。据此，她负责通过领导与全球癫痫业务相关的所有业务运营职能，创造、沟通和实施组织的愿景、使命和总体方向。在加入LivaNova之前，Bolton女士曾在包括三共制药、大冢制药和UCB制药在内的多家制药公司工作了十多年，在销售和产品领域担任的职位责任越来越大。博尔顿女士目前担任英国健康科技产业协会副主席。Bolton女士以优异成绩毕业于考文垂大学，获得生理学理学学士学位。
Stephanie Bolton,is the President, Global Epilepsy at LivaNova, a position she assumed in May 2023. She joined Cyberonics, Inc., one of LivaNova's two legacy companies, in April 2011 as a Senior Territory Manager, Epilepsy (March 2011 to April 2014) and over her tenure at LivaNova, assumed several senior, sales leadership positions. After serving as a Senior Territory Manager, she took on the role of Country Manager, UK and Ireland (April 2014 to September 2016), UKI Vice President (September 2016 to February 2018) and North Europe Vice President (February 2018 to October 2019). In October 2019, Ms. Bolton was appointed President, Europe (October 2019 to February 2021) and later became the President of LivaNova's International Region (February 2021 to May 2023) before she assumed her current role as President, Global Epilepsy, pursuant to which she is responsible for creating, communicating, and implementing the organization's vision, mission, and overall direction by leading all business operational functions as it relates to the global epilepsy business. Prior to joining LivaNova, Ms. Bolton spent over a decade working at various pharmaceutical companies including Sankyo Pharma, Otsuka Pharmaceuticals, and UCB Pharma, holding positions of increasing responsibility in the sales and product space. Ms. Bolton currently serves as the Vice Chair for the Association of British HealthTech Industries. Ms. Bolton graduated with Honors from Coventry University with a Bachelor of Science degree in physiology.- Stephanie Bolton，是LivaNova全球癫痫总裁，她于2023年5月担任该职位。她于2011年4月加入LivaNova的两家遗留公司之一的Cyberonics, Inc.，担任癫痫高级区域经理（2011年3月至2014年4月），并在LivaNova任职期间，担任过多个高级销售领导职务。在担任高级区域经理后，她担任英国和爱尔兰国家经理（2014年4月至2016年9月）、UKI副总裁（2016年9月至2018年2月）和北欧副总裁（2018年2月至2019年10月）。2019年10月，Bolton女士被任命为欧洲区总裁（2019年10月至2021年2月），之后成为LivaNova国际区总裁（2021年2月至2023年5月），之后她担任目前的全球癫痫总裁一职。据此，她负责通过领导与全球癫痫业务相关的所有业务运营职能，创造、沟通和实施组织的愿景、使命和总体方向。在加入LivaNova之前，Bolton女士曾在包括三共制药、大冢制药和UCB制药在内的多家制药公司工作了十多年，在销售和产品领域担任的职位责任越来越大。博尔顿女士目前担任英国健康科技产业协会副主席。Bolton女士以优异成绩毕业于考文垂大学，获得生理学理学学士学位。
- Stephanie Bolton,is the President, Global Epilepsy at LivaNova, a position she assumed in May 2023. She joined Cyberonics, Inc., one of LivaNova's two legacy companies, in April 2011 as a Senior Territory Manager, Epilepsy (March 2011 to April 2014) and over her tenure at LivaNova, assumed several senior, sales leadership positions. After serving as a Senior Territory Manager, she took on the role of Country Manager, UK and Ireland (April 2014 to September 2016), UKI Vice President (September 2016 to February 2018) and North Europe Vice President (February 2018 to October 2019). In October 2019, Ms. Bolton was appointed President, Europe (October 2019 to February 2021) and later became the President of LivaNova's International Region (February 2021 to May 2023) before she assumed her current role as President, Global Epilepsy, pursuant to which she is responsible for creating, communicating, and implementing the organization's vision, mission, and overall direction by leading all business operational functions as it relates to the global epilepsy business. Prior to joining LivaNova, Ms. Bolton spent over a decade working at various pharmaceutical companies including Sankyo Pharma, Otsuka Pharmaceuticals, and UCB Pharma, holding positions of increasing responsibility in the sales and product space. Ms. Bolton currently serves as the Vice Chair for the Association of British HealthTech Industries. Ms. Bolton graduated with Honors from Coventry University with a Bachelor of Science degree in physiology.
- Franco Poletti
Franco Poletti，是LivaNova心肺领域的总裁，他于2024年7月担任该职位。30多年前，Poletti先生加入了SOrin Group，这是LivaNova的两家传统公司之一。在过去20年中，Poletti先生在公司担任过多个高级领导职务，包括全球产品经理（1991年1月至2004年3月）、欧洲和日本销售副总裁（2008年1月至2012年12月）、欧洲销售副总裁（2013年1月至2016年9月）、心肺欧洲销售副总裁（2018年2月至2023年8月）和心肺临时总裁（2023年8月至2024年7月）。Poletti先生还管理其他公司特许经营权，包括心脏瓣膜（2013年1月至2022年3月）、心律管理（2016年10月至2018年1月）和神经调节（2016年10月至2022年3月）。在整个职业生涯中，Poletti先生在产品开发、产品定位和发布以及销售执行方面发展了核心竞争力。Poletti先生毕业于意大利米兰多拉的Istituto Tecnico Industriale G. Galilei。
Franco Poletti,is the President, Cardiopulmonary at LivaNova, a position he assumed in July 2024. Mr. Poletti joined Sorin Group, one of LivaNova's two legacy companies, more than 30 years ago. Over the last 20 years, Mr. Poletti has held several senior leadership positions within the Company, including Global Product Manager (January 1991 to March 2004), Vice President, Sales, Europe and Japan (January 2008 to December 2012), Vice President, Sales, Europe (January 2013 to September 2016), Vice President, Sales, Cardiopulmonary Europe (February 2018 to August 2023), and Interim President, Cardiopulmonary (August 2023 to July 2024). Mr. Poletti also managed other company franchises including Heart Valves (January 2013 to March 2022), Cardiac Rhythm Management (October 2016 to January 2018) and Neuromodulation (October 2016 to March 2022). Throughout his career, Mr. Poletti has developed core competencies in product development, product positioning and launch, and sales execution. Mr. Poletti graduated from Istituto Tecnico Industriale G. Galilei in Mirandola, Italy.- Franco Poletti，是LivaNova心肺领域的总裁，他于2024年7月担任该职位。30多年前，Poletti先生加入了SOrin Group，这是LivaNova的两家传统公司之一。在过去20年中，Poletti先生在公司担任过多个高级领导职务，包括全球产品经理（1991年1月至2004年3月）、欧洲和日本销售副总裁（2008年1月至2012年12月）、欧洲销售副总裁（2013年1月至2016年9月）、心肺欧洲销售副总裁（2018年2月至2023年8月）和心肺临时总裁（2023年8月至2024年7月）。Poletti先生还管理其他公司特许经营权，包括心脏瓣膜（2013年1月至2022年3月）、心律管理（2016年10月至2018年1月）和神经调节（2016年10月至2022年3月）。在整个职业生涯中，Poletti先生在产品开发、产品定位和发布以及销售执行方面发展了核心竞争力。Poletti先生毕业于意大利米兰多拉的Istituto Tecnico Industriale G. Galilei。
- Franco Poletti,is the President, Cardiopulmonary at LivaNova, a position he assumed in July 2024. Mr. Poletti joined Sorin Group, one of LivaNova's two legacy companies, more than 30 years ago. Over the last 20 years, Mr. Poletti has held several senior leadership positions within the Company, including Global Product Manager (January 1991 to March 2004), Vice President, Sales, Europe and Japan (January 2008 to December 2012), Vice President, Sales, Europe (January 2013 to September 2016), Vice President, Sales, Cardiopulmonary Europe (February 2018 to August 2023), and Interim President, Cardiopulmonary (August 2023 to July 2024). Mr. Poletti also managed other company franchises including Heart Valves (January 2013 to March 2022), Cardiac Rhythm Management (October 2016 to January 2018) and Neuromodulation (October 2016 to March 2022). Throughout his career, Mr. Poletti has developed core competencies in product development, product positioning and launch, and sales execution. Mr. Poletti graduated from Istituto Tecnico Industriale G. Galilei in Mirandola, Italy.
- Ahmet Tezel
Ahmet Tezel，于2024年5月加入LivaNova，担任首席创新官。Tezel博士拥有20年的业绩记录，指导团队在从减肥手术到外科眼科的不同医疗领域开发了市场领先的技术。在加入LivaNova之前，他曾在强生 MedTech、强生的医疗技术业务担任公司集团董事长（2022年11月至2024年3月），领导其全球研发和创新团队。其他研发职业经历包括高管级职位，例如在强生担任研发全球副总裁（2020年6月至2022年11月）、在爱尔康公司担任研发部门外科特许经营负责人（2017年2月至2020年6月）、在Allergan Inc.担任研发部门副总裁（2014年4月至2018年1月）、在Allergan Inc.担任研究与产品开发-医疗器械副总裁（2011年2月至2013年3月），在那里Tezel开发了III类植入物和复杂的医疗资本设备。他在不同医疗技术平台的创新转型方面有着良好的记录。2004年，他在加利福尼亚州圣巴巴拉的Inamed Corp.开始了研发科学家的职业生涯。Tezel博士在T ü rkiye的Bogazici大学获得化学工程学士和硕士学位，在透皮给药和疫苗接种领域获得加州大学圣巴巴拉分校的化学工程博士学位。
Ahmet Tezel,joined LivaNova in May 2024 as Chief Innovation Officer. Dr. Tezel has a 20-year track record, guiding teams that have developed market-leading technologies across diverse medical domains from bariatric surgery to surgical ophthalmology. Prior to joining LivaNova, he served as Company Group Chairman at Johnson & Johnson MedTech, Johnson & Johnson's medical technology businesses (November 2022 to March 2024), leading its Global R&D and Innovation teams. Other R&D career experience includes executive-level positions such as Worldwide Vice President Research and Development at Johnson & Johnson (June 2020 to November 2022), Surgical Franchise Head, Research and Development at Alcon, Inc. (February 2017 to June 2020), Vice-President of Research and Development, Intraocular Lenses (April 2014 to January 2018), and Vice President, Research & Product Development- Medical Device at Allergan Inc. (February 2011 to March 2013), where Tezel developed Class III implantables and complex medical capital equipment. He has an established track record of innovation turnarounds across diverse medical technology platforms. He began his career as an R&D scientist in 2004 at Inamed Corp. in Santa Barbara, California. Dr. Tezel earned bachelor's and master's degrees in chemical engineering from Bogazici University in Türkiye and a doctorate in chemical engineering from the University of California-Santa Barbara in the field of transdermal drug delivery and vaccination.- Ahmet Tezel，于2024年5月加入LivaNova，担任首席创新官。Tezel博士拥有20年的业绩记录，指导团队在从减肥手术到外科眼科的不同医疗领域开发了市场领先的技术。在加入LivaNova之前，他曾在强生 MedTech、强生的医疗技术业务担任公司集团董事长（2022年11月至2024年3月），领导其全球研发和创新团队。其他研发职业经历包括高管级职位，例如在强生担任研发全球副总裁（2020年6月至2022年11月）、在爱尔康公司担任研发部门外科特许经营负责人（2017年2月至2020年6月）、在Allergan Inc.担任研发部门副总裁（2014年4月至2018年1月）、在Allergan Inc.担任研究与产品开发-医疗器械副总裁（2011年2月至2013年3月），在那里Tezel开发了III类植入物和复杂的医疗资本设备。他在不同医疗技术平台的创新转型方面有着良好的记录。2004年，他在加利福尼亚州圣巴巴拉的Inamed Corp.开始了研发科学家的职业生涯。Tezel博士在T ü rkiye的Bogazici大学获得化学工程学士和硕士学位，在透皮给药和疫苗接种领域获得加州大学圣巴巴拉分校的化学工程博士学位。
- Ahmet Tezel,joined LivaNova in May 2024 as Chief Innovation Officer. Dr. Tezel has a 20-year track record, guiding teams that have developed market-leading technologies across diverse medical domains from bariatric surgery to surgical ophthalmology. Prior to joining LivaNova, he served as Company Group Chairman at Johnson & Johnson MedTech, Johnson & Johnson's medical technology businesses (November 2022 to March 2024), leading its Global R&D and Innovation teams. Other R&D career experience includes executive-level positions such as Worldwide Vice President Research and Development at Johnson & Johnson (June 2020 to November 2022), Surgical Franchise Head, Research and Development at Alcon, Inc. (February 2017 to June 2020), Vice-President of Research and Development, Intraocular Lenses (April 2014 to January 2018), and Vice President, Research & Product Development- Medical Device at Allergan Inc. (February 2011 to March 2013), where Tezel developed Class III implantables and complex medical capital equipment. He has an established track record of innovation turnarounds across diverse medical technology platforms. He began his career as an R&D scientist in 2004 at Inamed Corp. in Santa Barbara, California. Dr. Tezel earned bachelor's and master's degrees in chemical engineering from Bogazici University in Türkiye and a doctorate in chemical engineering from the University of California-Santa Barbara in the field of transdermal drug delivery and vaccination.